Company / Current Liabilities
ENDONOVO THERAPEUTICS, INC. Current Liabilities History
FY2011-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$33.4M
FY2022
5-year range
$15.5M / $33.4M
FY2018-FY2022
Trend
+88.6%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has fluctuated over the past 9 years, ranging from $1,293 in FY2011 to $33M in FY2022.
Based on SEC 10-K filings.
$33M in FY2022 with a 3-year CAGR of +12.2%.
Increased from $17M to $33M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +12.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +12.2%, indicating consistent growth.
- In FY2022, current liabilities increased 88.6% year-over-year.
- Lowest current liabilities in the period was in FY2011.
Company context
Key Data Points
- Altman Z-Score -76.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $33.4M | +88.6% |
| FY2021 | $17.7M | +5.2% |
| FY2020 | $16.8M | -28.8% |
| FY2019 | $23.6M | +52.6% |
| FY2018 | $15.5M | +77.5% |
| FY2016 | $8.7M | -8.1% |
| FY2015 | $9.5M | +108.3% |
| FY2014 | $4.6M | +352177.5% |
| FY2011 | $1.3K | - |
As of FY2022 · SEC 10-K · Updated Jun 29, 2026